In order to elucidate the role of anthracycline based combination chemotherapy regimens for the treatment of follicular lymphoma we conducted a retrospective study on a large series of patients with a histologically confirmed diagnosis of follicular lymphoma. The Italian lymphoma intergroup (ILI) promoted a retrospective study of patients with follicular lymphoma treated in cooperative trials between 1985 and 1996. Six hundred and thirty three cases were treated with an anthracycline-containing regimen and 128 patients were treated without anthracyclines. The two groups were prognostically comparable; in particular, no difference was observed according to both IPI and ILI prognostic index. Results showed a complete remission (CR) rate for patients treated with anthracyclines was 69.2% and overall response rate was 92.5%. After a median follow-up of 51 months (54 months for patients still alive), the 5- and 10-year overall survival (OS) rates were 80 and 66%, respectively. Disease-free survival (DFS) and failure-free survival (FFS) rates at 5 years were 61 and 49%, respectively. In the group of patients treated with combination chemotherapy not including anthracyclines, the CR rate was 67.5% and the overall response rate was 85.4%. A longer OS (80% at 5 years) was observed in patients treated with anthracyclines compared to 67% OS rate in patients treated without anthracyclines (p=0.0004). FFS was significantly longer in patients treated with anthracyclines (49 vs. 34% p=0.006 ). Patients treated with anthracyclines with low or intermediate risk according to ILI prognostic index showed a significantly longer OS (p=0.0001 and p=0.0009, respectively); those in the high-risk group showed a trend for a longer survival. In conclusion, this retrospective study shows that patients with follicular lymphoma treated with an anthracycline containing regimen had a better outcome compared to patients treated with other combination regimens non including anthracyclines in terms of CRs, OS and FFS. On the basis of these results anthracycline-containing regimens (ACR) should be considered as the standard treatment of patients with advanced follicular lymphoma.

The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: Retrospective study of the Intergruppo Italiano Linfomi on 761 cases / Rigacci, L; Federico, Massimo; Martelli, M; Zinzani, Pl; Cavanna, L; Bellesi, G; Merli, F; Alterini, R; Petrucci, Mt; Tani, M; Liberati, Alessandro; Vitolo, U; Pavone, V; Cuneo, A; Chisesi, T; Brugiatelli, M.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 44 (11):(2003), pp. 1911-1917. [10.1080/1042819031000123564]

The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: Retrospective study of the Intergruppo Italiano Linfomi on 761 cases

FEDERICO, Massimo;LIBERATI, Alessandro;
2003

Abstract

In order to elucidate the role of anthracycline based combination chemotherapy regimens for the treatment of follicular lymphoma we conducted a retrospective study on a large series of patients with a histologically confirmed diagnosis of follicular lymphoma. The Italian lymphoma intergroup (ILI) promoted a retrospective study of patients with follicular lymphoma treated in cooperative trials between 1985 and 1996. Six hundred and thirty three cases were treated with an anthracycline-containing regimen and 128 patients were treated without anthracyclines. The two groups were prognostically comparable; in particular, no difference was observed according to both IPI and ILI prognostic index. Results showed a complete remission (CR) rate for patients treated with anthracyclines was 69.2% and overall response rate was 92.5%. After a median follow-up of 51 months (54 months for patients still alive), the 5- and 10-year overall survival (OS) rates were 80 and 66%, respectively. Disease-free survival (DFS) and failure-free survival (FFS) rates at 5 years were 61 and 49%, respectively. In the group of patients treated with combination chemotherapy not including anthracyclines, the CR rate was 67.5% and the overall response rate was 85.4%. A longer OS (80% at 5 years) was observed in patients treated with anthracyclines compared to 67% OS rate in patients treated without anthracyclines (p=0.0004). FFS was significantly longer in patients treated with anthracyclines (49 vs. 34% p=0.006 ). Patients treated with anthracyclines with low or intermediate risk according to ILI prognostic index showed a significantly longer OS (p=0.0001 and p=0.0009, respectively); those in the high-risk group showed a trend for a longer survival. In conclusion, this retrospective study shows that patients with follicular lymphoma treated with an anthracycline containing regimen had a better outcome compared to patients treated with other combination regimens non including anthracyclines in terms of CRs, OS and FFS. On the basis of these results anthracycline-containing regimens (ACR) should be considered as the standard treatment of patients with advanced follicular lymphoma.
44 (11)
1911
1917
The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: Retrospective study of the Intergruppo Italiano Linfomi on 761 cases / Rigacci, L; Federico, Massimo; Martelli, M; Zinzani, Pl; Cavanna, L; Bellesi, G; Merli, F; Alterini, R; Petrucci, Mt; Tani, M; Liberati, Alessandro; Vitolo, U; Pavone, V; Cuneo, A; Chisesi, T; Brugiatelli, M.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 44 (11):(2003), pp. 1911-1917. [10.1080/1042819031000123564]
Rigacci, L; Federico, Massimo; Martelli, M; Zinzani, Pl; Cavanna, L; Bellesi, G; Merli, F; Alterini, R; Petrucci, Mt; Tani, M; Liberati, Alessandro; Vitolo, U; Pavone, V; Cuneo, A; Chisesi, T; Brugiatelli, M.
File in questo prodotto:
File Dimensione Formato  
The role of anthracyclines.......pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 599.55 kB
Formato Adobe PDF
599.55 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/4944
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact